| Gene name: | SFRP1 |
| Aging type: | Accelerate |
| Aging characteristic: |
| Tissue type: | -- |
| Cell name: | CSC |
| Experiment: | SA-β-gal activity assay//Western blot//ELISA |
| Description: | We also confirmed the up-regulation of senescence markers p16, p21, phosphorylated p53, and SA-β-gal in sFRP1-treated CDCs.Importantly, sFRP1-treated CDCs presented SASP, which was characterized by up-regulation of IL-6 and IL-1b, and was consistent with anti-cancer drug-induced cellular senescence. |
| Regulatory pathway: | WNT |
| R-AG-Pathway: | Downregulation |
| Official symbol(s): | Wnt |
| Pathway experiment: | Western blot |
| Pathway description: | Different concentrations of recombinant human sFRP1 were administered to CDC cultures for 1 and 48 h. Recombinant sFRP1 treatment caused an increase in phosphorylated b-catenin and a decrease in phosphorylated GSK3b in young patients-derived CDCs,indicating that exogenous sFRP1 inhibited canonical Wnt signaling. |
Annotation:
Loading,please wait...